Clinical Trials Logo

Clinical Trial Summary

This study evaluates the effects of ten hours C-mill training on gait adaptability in participants with hereditary spastic paraplegia (HSP). Half of the participants start with five weeks of C-mill training (ten 1-hour sessions). The other participants are placed on a waiting list, which is followed by the same five weeks of C-mill training (ten 1-hour sessions). It is hypothesized that ten hours of context specific C-mill training is effective in improving gait adaptability in participants with pure HSP.


Clinical Trial Description

Hereditary spastic paraplegia (HSP) is a relatively common, slowly progressive movement disorder that seriously impacts on gait capacity. Patients with HSP experience incremental muscle stiffness, muscle weakness and balance problems and, as a consequence, increasing difficulties to adjust their gait pattern to changing environmental demands. This is a major problem as such 'gait adaptability' is critical for independent and safe mobility in daily life. Impaired gait adaptability will also result in falls and fall-related injuries and reduce quality of life. Therefore, there is an urgent need for evidence-based rehabilitation interventions to improve gait adaptability in patients with HSP. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-Mill, a treadmill providing augmented reality via visual and acoustic cues. Objectives This study aims to promote an essential step towards evidence-based and individually tailored gait rehabilitation in participants with hereditary spastic paraparesis. The objectives are twofold: 1. To study the effect of ten 1-hour sessions C-Mill training on gait adaptability in participants with pure-HSP. 2. To study the effect of ten 1-hour sessions C-Mill training on spatiotemporal and functional capacity parameters and to identify key-determinants of C-Mill training efficacy in participants with pure-HSP. It is hypothesized that ten hours of context specific C-mill training is effective in improving gait adaptability in participants with pure HSP, as measured with the obstacle subtask of the emory functional ambulation profile (E-FAP). Sample size calculation is based on previous studies concerning the effects of gait adaptability interventions on the obstacle subtask of the E-FAP. A total of 32 participants is sufficient to demonstrate an expected improvement on the obstacle subtask score of the E-FAP. To allow a 10% attrition rate, 36 participants will be included. Participants will be recruited from the Radboud Expert Centre of Genetic Movement Disorders (part of the ERN-RND) which has specific HSP expertise. The treating physician of the patient will ask whether the investigator may contact the patient. Furthermore, mailings through the HSP patient group, that is part of the patient organization "Spierziekten Nederland", will be sent to their members with HSP. If patients are interested in participating, they can contact the investigator and will be informed via an information letter (to which the informed consent form is attached). Participants will then have two weeks to consider their decision whether to participate. After the two week period, the investigator will contact them about their decision. Data will be coded numerically (e.g. HSP01, HSP02) and an identification code list will be used to link the data to the participant. The key to the code will be safeguarded by the investigators. The project leader and all other investigators will have access to the source data. Data will be kept for fifteen years. The handling of data will comply with the Dutch Personal Data Protection Act and participants' privacy will be protected. The monitoring will be performed according to NFU guidelines for negligible risk intensity. Descriptive data analysis will be used to outline characteristics of both intervention groups. The effect of gait adaptability training on primary and secondary outcomes will be tested using ANCOVA. Post-intervention measurements will be used as dependent variables and Group (C-Mill versus waiting list) and pre-intervention measurements as independent between-subjects factors. Time will be tested as a within-subjects factor. The retention of gait adaptability training will be tested by merging both groups and using a repeated measures ANOVA with Time as a within-subjects factor (C-Mill group: measurements 1, 2 and 3; waiting list: measurements 2, 3 and 4). Post-hoc tests will be performed in the case of significant main or interaction effects, using paired t-tests. Fall rates will be processed descriptively. Depending on the distribution of the data, the rate of near falls may be analyzed using Wilcoxon signed rank test. In addition, to determine key determinants of C-Mill training efficacy, a stepwise linear regression analysis will be performed with training-induced change in gait adaptability (relative change of the obstacle subtask of the E-FAP) as the dependent variable. Univariate analyses will be performed to select the best factors from the available demographic and clinical characteristics. Adverse events All adverse events reported spontaneously by the participants or observed by the investigator or his staff will be recorded. The sponsor will report the SAEs through the web portal ToetsingOnline to the accredited METC that approved the protocol, within seven days of first knowledge for SAEs that result in death or are life threatening followed by a period of maximum of 8 days to complete the initial preliminary report. All other SAEs will be reported within a period of maximum 15 days after the sponsor has first knowledge of the serious adverse events. The risk associated with participation will be negligible, according to the risk classification of the NFU. Burden associated with the measurements will be limited, as the number of measurements will be relatively low. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04180098
Study type Interventional
Source Radboud University Medical Center
Contact
Status Completed
Phase N/A
Start date December 1, 2019
Completion date April 15, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT05373082 - Identification of Modifying Factors in Hereditary Spastic Paraplegia
Recruiting NCT03981276 - Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
Terminated NCT02859428 - Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
Completed NCT03104088 - Studying Cognition in SPG4
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Completed NCT02604186 - Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Phase 2/Phase 3
Completed NCT04912609 - Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)
Recruiting NCT03206190 - The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4 N/A
Completed NCT03627416 - Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy N/A
Recruiting NCT04875416 - Phenotype, Genotype and Biomarkers 2
Withdrawn NCT05411627 - A Pilot Study of Shockwave Therapy in HSP N/A
Completed NCT03961906 - Physiotherapy in Hereditary Spastic Paraplegia Phase 2
Completed NCT05767268 - Assessment of the Psychophysical State During Rehabilitation Treatment With Lokomat
Completed NCT02852278 - A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Completed NCT05613114 - Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia N/A
Completed NCT00023075 - Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis N/A
Recruiting NCT04712812 - Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
Recruiting NCT05354622 - Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Enrolling by invitation NCT02327845 - Phenotype, Genotype & Biomarkers in ALS and Related Disorders